Menu
NeuroGenesis is a clinical stage cellular therapy company focusing on a proprietary subpopulation of bone marrow stem cells that are selected and enhanced to become remyelinating & regenerative biofactory cells.
The platform NG CELL™️ technology is optimized to treat central nervous system diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
Proprietary NG
CELL™ Platform
Clinical Pipeline
Cell Therapies for Demyelinating & Neurodegenerative Diseases
Promoting Regeneration
of Myelin & Neuronal Cells
Neurogenesis is developing a cutting-edge approach to sustained delivery of unparalleled levels of remyelinating & regeneration proteins using the patient’s own stem cells. The technology is called NG CELL™. It entails collecting bone marrow from the patient. Then by utilizing a proprietary process, a unique subpopulation of bone marrow cells is identified and enhanced to remyelinating & regenerating biofactory cells (NG Cells). The NG Cells are expanded to tens of millions and injected directly into the spinal cord fluid, home-in on the damaged area, take up residence for up to three months and produce sustained, massive amounts of remyelinating & neuronal growth proteins in order to in-situ remyelinate, regenerate and repair.
The NG Cells have remyelinating, neuroprotective and neuro-regenerative properties. The cells can prevent neurons and oligodendrocytes from apoptosis via the release of remyelinating, regeneration and anti-apoptotic molecules (CNTF, BDNF, and others), and have anti-proliferative effects on microglial cells and astrocytes, resulting in the induction of a neuroprotective microenvironment.
